Which US companies are pulling back on diversity initiatives?
A growing number of prominent companies have scaled back or set aside the diversity, equity and inclusion initiatives that ...
Stifel maintains Buy on Iovance Biotherapeutics, target at $21
Stifel analysts maintained their Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA), currently trading at $5.24, with a steady price target of $21.00. According to InvestingPro data, analyst targets ...